Semathera

Uxbridge, Ontario, Canada

Company profile

Semathera company profile

SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).

Business identity

Website: http://semathera.com
Contact email: [email protected]
Operating status: Active
Company type: For Profit
Employee range: 00001-00010 employees
Founded: 2016-01-01

LinkedIn X

Headquarters

Headquarters: Uxbridge, Ontario, Canada
Postal code: H4X 1Z5
Country code: CA
Continent: North America

Capital profile

Funding and company signals

Funding rounds: 2
Total equity funding: $3.6M
Last funding: Series Unknown / $2.6M / 2018-03-26
Last equity funding: Series Unknown / $2.6M
Investors: 2
Lead investors: 2
Founders: 1
Articles: 1

Categories and groups

Biotechnology Diabetes Therapeutics Biotechnology Health Care Science and Engineering

Founders and investors

Founders

Przemyslaw Sapieha

Lead investors

AmorchemSenju Pharmaceutical

Investors

AmorchemSenju Pharmaceutical

People at this company

Preview only. Contact details are available after you sign in.

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Shipment records and coverage can change as the dataset is updated.